Status:
RECRUITING
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
Lead Sponsor:
Istituto Oncologico Veneto IRCCS
Conditions:
Prostate Cancer
Bladder Cancer
Eligibility:
All Genders
18-99 years
Brief Summary
Patients previously treated with robotic surgery for urological cancers such as prostate, bladder and kidney cancer will be enrolled, in particular patients operated in the last twelve months will be ...
Detailed Description
The rationale behind the design of this study is to define a snapshot of the impact of robotic surgery performed in uro-oncology patients on financial toxicity assessed through PROFFIT questionnaire. ...
Eligibility Criteria
Inclusion
- Male or female ≥ 18 years of age;
- ECOG PS 0-1
- Diagnosis of urological neoplasm (prostate, bladder and kidney cancer) treated with robotic surgery (robot-assisted prostatectomy, robot-assisted radical cystectomy, robot-assisted radical or partial nephrectomy) in the last twelve months;
- Subjects willing to sign informed consent.
Exclusion
- Patients unable to fill out questionnaires (e.g., severe mental illness or cognitive dysfunction);
- Patients suffering from concomitant malignancies in other sites and in active treatment;
- Patients with a history of cancer not currently on active treatment may be enrolled.
Key Trial Info
Start Date :
June 18 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06955910
Start Date
June 18 2025
End Date
June 1 2026
Last Update
July 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Oncologico Veneto
Padua, Italy/Padova, Italy, 35128